TY - JOUR
T1 - Emerging roles of RNA-binding proteins in fatty liver disease
AU - Adesanya, Oluwafolajimi
AU - Das, Diptatanu
AU - Kalsotra, Auinash
N1 - A.K is supported by the National Institute of Health grants (R01HL126845, R01AA010154, and R21HD104039), Muscular Dystrophy Association grant 1072487 (https://doi.org/10.55762/MDA.1072487.pc.gr.174106), the Planning Grant Award from the Cancer Center@Illinois, the William C. Rose Professorship, and the Beckman Fellowship from the Center for Advanced Study at the University of Illinois Urbana-Champaign. The authors thank members of the Kalsotra laboratory for helpful discussions and comments on the manuscript.
PY - 2024/3
Y1 - 2024/3
N2 - A rampant and urgent global health issue of the 21st century is the emergence and progression of fatty liver disease (FLD), including alcoholic fatty liver disease and the more heterogenous metabolism-associated (or non-alcoholic) fatty liver disease (MAFLD/NAFLD) phenotypes. These conditions manifest as disease spectra, progressing from benign hepatic steatosis to symptomatic steatohepatitis, cirrhosis, and, ultimately, hepatocellular carcinoma. With numerous intricately regulated molecular pathways implicated in its pathophysiology, recent data have emphasized the critical roles of RNA-binding proteins (RBPs) in the onset and development of FLD. They regulate gene transcription and post-transcriptional processes, including pre-mRNA splicing, capping, and polyadenylation, as well as mature mRNA transport, stability, and translation. RBP dysfunction at every point along the mRNA life cycle has been associated with altered lipid metabolism and cellular stress response, resulting in hepatic inflammation and fibrosis. Here, we discuss the current understanding of the role of RBPs in the post-transcriptional processes associated with FLD and highlight the possible and emerging therapeutic strategies leveraging RBP function for FLD treatment. This article is categorized under: RNA in Disease and Development > RNA in Disease.
AB - A rampant and urgent global health issue of the 21st century is the emergence and progression of fatty liver disease (FLD), including alcoholic fatty liver disease and the more heterogenous metabolism-associated (or non-alcoholic) fatty liver disease (MAFLD/NAFLD) phenotypes. These conditions manifest as disease spectra, progressing from benign hepatic steatosis to symptomatic steatohepatitis, cirrhosis, and, ultimately, hepatocellular carcinoma. With numerous intricately regulated molecular pathways implicated in its pathophysiology, recent data have emphasized the critical roles of RNA-binding proteins (RBPs) in the onset and development of FLD. They regulate gene transcription and post-transcriptional processes, including pre-mRNA splicing, capping, and polyadenylation, as well as mature mRNA transport, stability, and translation. RBP dysfunction at every point along the mRNA life cycle has been associated with altered lipid metabolism and cellular stress response, resulting in hepatic inflammation and fibrosis. Here, we discuss the current understanding of the role of RBPs in the post-transcriptional processes associated with FLD and highlight the possible and emerging therapeutic strategies leveraging RBP function for FLD treatment. This article is categorized under: RNA in Disease and Development > RNA in Disease.
KW - hepatocellular dysfunction
KW - liver cancer
KW - liver cirrhosis
KW - NASH
KW - post-transcriptional gene regulation
KW - R-loops
KW - RNA processing
UR - http://www.scopus.com/inward/record.url?scp=85190301019&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85190301019&partnerID=8YFLogxK
U2 - 10.1002/wrna.1840
DO - 10.1002/wrna.1840
M3 - Review article
C2 - 38613185
SN - 1757-7004
VL - 15
JO - Wiley interdisciplinary reviews. RNA
JF - Wiley interdisciplinary reviews. RNA
IS - 2
M1 - e1840
ER -